$BSEM

BioStem Technologies (BSEM) announced the issuance of one U.S. patent and four notices of allowance for additional patent applications, expanding its intellectual property portfolio in placental and umbilical cord tissue technologies for wound care, surgical, and joint applications. The company plans to continue investing in patent protection and innovation. BioStem has over 100 patents and patent applications worldwide.

BioStem Technologies, Inc. (BSEM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules POMPANO BEACH, Fla., Sept. 30, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company

BioStem Technologies (BSEM) announced a $3M private placement of 735,296 shares and warrants at $4.08 per share, with warrants exercisable at $3.83. Proceeds will be used for working capital. The offering is expected to close on September 30, 2026. H.C. Wainwright & Co. is the placement agent.

BioStem Technologies, Inc. (BSEM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility POMPANO BEACH, Fla., Sept. 18, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the develo

BioStem Technologies (Nasdaq: BSEM) secured a $40 million Committed Equity Facility with Roth Principal Investments. The company can issue up to $40 million in shares, subject to Nasdaq rules and conditions. Proceeds will be used for working capital and general corporate purposes. BioStem filed a registration statement for the resale of shares.

BioStem Technologies (BSEM) expanded hospital access for VENDAJE and VENDAJE AC through contracts with Vizient and Premier, two large U.S. GPOs. Both products are now available for order under these contracts. The move is expected to support BioStem's commercial strategy and broaden its wound care product reach. BSEM shares closed at $3.61 on Thursday and were up 9.42% in premarket trading.

BioStem Technologies (BSEM) reported Q2 2026 revenue of $7.9M, up 29% sequentially, driven by Neox and Clarix product sales. The company raised full-year 2026 revenue guidance to $26M-$29M and uplisted to Nasdaq. BSEM also completed a $2.5M private placement and held $7.0M in cash as of Q2 2026.

BioStem Technologies, Inc. (BSEM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BioStem Technologies Reports Second Quarter 2026 Financial Results Generates 29% sequential revenue growth, increasing to $7.9 million; Raises full-year 2026 revenue guidance Uplists to Nasdaq Capital Market POMPANO BEACH, FL, August 12, 2026 (GLOBE NEWSWIRE) — BioSt

BioStem Technologies Inc. (OTC: BSEM) said it filed a Form 10 registration statement with the SEC to register its common stock and reaffirmed plans to pursue a Nasdaq listing. The filing is not yet effective and will become effective after SEC review. Until uplisting, BSEM shares continue trading on the OTC market.

POMPANO BEACH, Fla., April 21, 2025 ( GLOBE NEWSWIRE ) -- BioStem Technologies, Inc. ( OTC: BSEM ) , a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, is pleased to announce that its Chief Executive ...